Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity

RICCARDO MOIA; E. Boggio; L. Gigliotti; E. Crisa; Paoli L. De; Casaluci G. Margiotta; Roberta ROLLA; A. Patriarca; Gianluca GAIDANO; Umberto DIANZANI; R. Bruna

doi:10.1002/hon.2700

Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity

RICCARDO MOIA
, E. Boggio
, L. Gigliotti
, E. Crisa
, Paoli L. De
, Casaluci G. Margiotta
, Roberta ROLLA
, A. Patriarca
, Gianluca GAIDANO
, Umberto DIANZANI
, R. Bruna

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Lingua originale	Inglese
pagine (da-a)	204-206
Numero di pagine	3
Rivista	Hematological Oncology
Volume	38
Numero di pubblicazione	2
DOI	https://doi.org/10.1002/hon.2700
Stato di pubblicazione	Pubblicato - 2020

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Keywords

antibodies response
multiple myeloma
rasburicase
tumor lysis syndrome

Accesso al documento

10.1002/hon.2700

http://hdl.handle.net/11579/111817

Altri file e collegamenti

handle

Cita questo

@article{e8ebf20ed1e04623a6971ff920db3d12,

title = "Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity",

keywords = "antibodies response, multiple myeloma, rasburicase, tumor lysis syndrome, antibodies response, multiple myeloma, rasburicase, tumor lysis syndrome",

author = "RICCARDO MOIA and E. Boggio and L. Gigliotti and E. Crisa and De, \{Paoli L.\} and Margiotta, \{Casaluci G.\} and Roberta ROLLA and A. Patriarca and Gianluca GAIDANO and Umberto DIANZANI and R. Bruna",

note = "Funding Information: This work was supported by Molecular bases of disease dissemination in lymphoid malignancies to optimize curative therapeutic strategies (5 × 1000 No. 21198) and IG 20714, Associazione Italiana per la Ricerca sul Cancro Foundation, Milan, Italy; Progetti di Rilevante Interesse Nazionale (PRIN), (2015ZMRFEA), Rome, Italy; Fondazione Cariplo (2017‐0535), Milan, Italy; Partially founded by the AGING Project—Department of Excellence—DIMET, Universit{\`a} del Piemonte Orientale, Novara, Italy; and Ricerca Finalizzata 2018 (project RF‐2018‐12365790), MoH, Rome, Italy. ",

year = "2020",

doi = "10.1002/hon.2700",

language = "English",

volume = "38",

pages = "204--206",

journal = "Hematological Oncology",

issn = "0278-0232",

publisher = "John Wiley and Sons Ltd",

number = "2",

}

TY - JOUR

T1 - Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity

AU - MOIA, RICCARDO

AU - Boggio, E.

AU - Gigliotti, L.

AU - Crisa, E.

AU - De, Paoli L.

AU - Margiotta, Casaluci G.

AU - ROLLA, Roberta

AU - Patriarca, A.

AU - GAIDANO, Gianluca

AU - DIANZANI, Umberto

AU - Bruna, R.

N1 - Funding Information: This work was supported by Molecular bases of disease dissemination in lymphoid malignancies to optimize curative therapeutic strategies (5 × 1000 No. 21198) and IG 20714, Associazione Italiana per la Ricerca sul Cancro Foundation, Milan, Italy; Progetti di Rilevante Interesse Nazionale (PRIN), (2015ZMRFEA), Rome, Italy; Fondazione Cariplo (2017‐0535), Milan, Italy; Partially founded by the AGING Project—Department of Excellence—DIMET, Università del Piemonte Orientale, Novara, Italy; and Ricerca Finalizzata 2018 (project RF‐2018‐12365790), MoH, Rome, Italy.

PY - 2020

Y1 - 2020

KW - antibodies response

KW - multiple myeloma

KW - rasburicase

KW - tumor lysis syndrome

KW - antibodies response

KW - multiple myeloma

KW - rasburicase

KW - tumor lysis syndrome

UR - https://iris.uniupo.it/handle/11579/111817

U2 - 10.1002/hon.2700

DO - 10.1002/hon.2700

M3 - Article

SN - 0278-0232

VL - 38

SP - 204

EP - 206

JO - Hematological Oncology

JF - Hematological Oncology

IS - 2

ER -